Your reference: 57318

19 August 2022
Melissa Kostopoulos
Compliance Adviser, Listings Compliance (Melbourne)
ASX Compliance Pty Ltd

By email: ListingsComplianceMelbourne@asx.com.au

Dear Ms Kostopoulos

Antisense Therapeutics Limited ('ANP'): Query

We refer to your letter dated 17 August 2022 regarding **Antisense Therapeutics Limited** (the 'Company' or 'ANP') recent requests for a trading halt and a voluntary suspension and related matters. Capitalised terms which have not otherwise been defined have the meaning given in your letter. The Company's responses to the numbered questions set out in the letter are as follows:

1. At the time of the Trading Halt Request, what actions remained to be carried out to allow the making of the announcement intended to lift the Trading Halt?

   - Collation and verification of outcomes
   - Reviewing the outcomes and the announcement with key opinion leader for input and incorporation of his quotation
   - Finalisation of the specification and lodgement of US patent applications
   - Finalisation and approval of announcement

2. Is the data relating to the Long COVID-19 study referred to in the Trading Halt Request available?

   The Trading Halt Request referred to a pending "announcement in relation to reporting outcomes of the Long COVID-19 strategic collaboration announced on 24 February 2022." "Outcomes" referred to the identification of target markers and that information (to the extent it is not considered a trade secret) is included in the submitted announcement and presentation. The Long COVID-19 strategic collaboration is not a clinical trial and does not generate the data normally associated with a clinical trial.

2.1 If the answer to question 2 is 'yes', why is the data not contained in Draft Market Release?

The company included what it considered to be the material outcomes in the Draft Market Release. Background information on the study is contained within the presentation.

2.2 If the answer to question 2 is 'no':

2.2.1 When is the data expected to become available? If applicable, please note Listing Rule 3.1 that requires information that a reasonable person would expect to have a material effect on the price or value of ANP's securities to be disclosed immediately (subject to specified exceptions).

Not applicable.

2.2.2 Did ANP expect the data to be available in time to be included in the announcement to lift the Trading Halt, and if not why did ANP's Trading Halt Request refer to 'reporting outcomes' as the basis for the request?

Not applicable.

2.2.3 Please advise how ANP is able to file the patent applications referred to in the Draft Market Release if the data is not available.

Not applicable.

3. Please provide details of the patent applications referred to in the Draft Market Release.

The titles of the three patent applications are:

"Biomarkers and Uses thereof"

"Methods for treating neurological post-acute sequelae of COVID-19 (NPASC)"

"Methods for diagnosing and treating neurological post-acute sequelae of COVID-19 (NPASC)"

Date of submission for each was Tuesday 16 August 2022 in the USA, notified to the Company in Australia on Wednesday 17 August 2022.
US provisional applications titles would otherwise not be publicly available until 18 months after filing.

4. Please provide ASX Listings Compliance an updated draft market release that includes the relevant data.

   Updated market release and presentation attached.

5. Please confirm that ANP is complying with the Listing Rules and, in particular, Listing Rule 3.1.

   Consistent with the Company's Communication and Disclosure Policy available at www.antisense.com.au/corporate-governance/, the Company continues to be in compliance with the Listing Rules and, in particular, Listing Rule 3.1.

6. Please confirm that ANP's responses to the questions above have been authorised and approved in accordance with its published continuous disclosure policy or otherwise by its board or an officer of ANP with delegated authority from the board to respond to ASX on disclosure matters.

   This response has been authorised and approved by the Chair and Managing Director & Chief Executive Officer and in accordance with the Communication and Disclosure Policy.

Yours Sincerely

Phillip Hains
Company Secretary

17 August 2022

Reference: 57318

Mr Phillip Hains
Company Secretary
Antisense Therapeutics Limited
Level 1, 14 Wallace Avenue
Toorak, Victoria 3142

By email: Phillip@thecfo.com.au

Dear Mr Hains

Antisense Therapeutics Limited ('ANP'): Query

ASX Limited ('ASX') refers to the following:

A. ANP's request for a trading halt released on the ASX Market Announcements Platform ('MAP') together with ASX's market announcement regarding the trading halt on 15 August 2022 (ANP's request for a trading halt, the 'Trading Halt Request', and the trading halt imposed by ASX, the 'Trading Halt'). The basis for the Trading Halt Request was stated to be '*pending an announcement in relation to reporting outcomes of the Long COVID-19 strategic collaboration announced on 24 February 2022*'.

B. ANP's request for a voluntary suspension released on MAP together with ASX's market announcement regarding the voluntary suspension on 17 August 2022 ('Voluntary Suspension').

C. ANP's draft announcement titled 'Long COVID-19 study identifies novel blood markers as potential diagnostic and therapeutic targets' forwarded to ASX Listings Compliance on 16 August 2022 for review that intended to lift the Trading Halt ('Draft Market Release').

D. ASX's policy position on the use of trading halts and voluntary suspensions, which is detailed in section 4.6 and 4.7 of Guidance Note 8 *Continuous Disclosure*: Listing Rules 3.1 – 3.1B. In particular, the Guidance Note states that:

> '*Not all announcements an entity may wish to make will warrant a trading halt or voluntary suspension. It is for this reason that when an entity requests ASX for a trading halt or voluntary suspension to allow it the time it needs to prepare an announcement under Listing Rule 3.1, ASX will usually ask the entity to outline the nature of the information in question and assess for itself whether the circumstances warrant the granting of a trading halt or voluntary suspension*'.

E. ASX's *Listed@ASX Compliance Update no.11/21* ('Listed Update') dated 16 December 2021 that outlines ASX's position in relation to disclosure regarding patent applications. In particular, the Listed Update states that:

> '*If a listed entity wishes to update the market on the status of a patent application prior to its grant then it should do so in its quarterly reports or other periodic disclosure. Stand-alone announcements concerning such applications, whether marked "price-sensitive" or not, are likely to result in further action from ASX (which may include the announcement being rejected or ASX sending a query letter requiring the entity to justify why it considers it to have been appropriate to release the announcement on MAP)*'.

Questions and Request for information

Having regard to the above, ASX asks ANP to respond separately to each of the following questions and requests for information:

1. At the time of the Trading Halt Request, what actions remained to be carried out to allow the making of the announcement intended to lift the Trading Halt?
2. Is the data relating to the Long COVID-19 study referred to in the Trading Halt Request available?
    2.1 If the answer to question 2 is 'yes', why is the data not contained in Draft Market Release?
    2.2 If the answer to question 2 is 'no':
        2.2.1 When is the data expected to become available? If applicable, please note Listing Rule 3.1 that requires information that a reasonable person would expect to have a material effect on the price or value of ANP's securities to be disclosed immediately (subject to specified exceptions).
        2.2.2 Did ANP expect the data to be available in time to be included in the announcement to lift the Trading Halt, and if not why did ANP's Trading Halt Request refer to 'reporting outcomes' as the basis for the request?
        2.2.3 Please advise how ANP is able to file the patent applications referred to in the Draft Market Release if the data is not available.
3. Please provide details of the patent applications referred to in the Draft Market Release.
4. Please provide ASX Listings Compliance an updated draft market release that includes the relevant data.
5. Please confirm that ANP is complying with the Listing Rules and, in particular, Listing Rule 3.1.
6. Please confirm that ANP's responses to the questions above have been authorised and approved in accordance with its published continuous disclosure policy or otherwise by its board or an officer of ANP with delegated authority from the board to respond to ASX on disclosure matters.

When and where to send your response

This request is made under Listing Rule 18.7. Your response is required as soon as reasonably possible and, in any event, by no later than **9:30 AM AEST Monday, 22 August 2022**. You should note that if the information requested by this letter is information required to be given to ASX under Listing Rule 3.1 and it does not fall within the exceptions mentioned in Listing Rule 3.1A, ANP's obligation is to disclose the information 'immediately'. This may require the information to be disclosed before the deadline set out in the previous paragraph and may require ANP to request a trading halt immediately.

Your response should be sent to me by e-mail at **ListingsComplianceMelbourne@asx.com.au**. It should not be sent directly to the ASX Market Announcements Office. This is to allow me to review your response to confirm that it is in a form appropriate for release to the market, before it is published on the ASX Market Announcements Platform.

Listing Rules 3.1 and 3.1A

In responding to this letter, you should have regard to ANP's obligations under Listing Rules 3.1 and 3.1A and also to Guidance Note 8 *Continuous Disclosure*: Listing Rules 3.1 – 3.1B. It should be noted that ANP's obligation to disclose information under Listing Rule 3.1 is not confined to, nor is it necessarily satisfied by, answering the questions set out in this letter.

Release of correspondence between ASX and entity

We reserve the right to release a copy of this letter, your reply and any other related correspondence between us to the market under listing rule 18.7A.

Questions

If you have any questions in relation to the above, please do not hesitate to contact me.

Yours sincerely

Melissa Kostopoulos
Compliance Adviser, Listings Compliance (Melbourne)